Priorities for the Priority Review Voucher.
Abstract
The U.S. Congress created the priority review voucher program in 2007 to encourage
development of drugs for neglected diseases. Under the voucher program, the developer
of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food
and Drug Administration receives a bonus priority review voucher for another drug.
As of 2016, four vouchers have sold for an average price of $200 million. Recent experience
with the voucher program indicates strengths and weaknesses of the program, as well
as a need for legislative changes.
Type
Journal articleSubject
Anti-Infective AgentsDrug Approval
Drug Discovery
Humans
Neglected Diseases
Orphan Drug Production
Pharmaceutical Preparations
Tropical Medicine
United States
United States Food and Drug Administration
Permalink
https://hdl.handle.net/10161/15437Published Version (Please cite this version)
10.4269/ajtmh.16-0600Publication Info
Ridley, David B (2017). Priorities for the Priority Review Voucher. Am J Trop Med Hyg, 96(1). pp. 14-15. 10.4269/ajtmh.16-0600. Retrieved from https://hdl.handle.net/10161/15437.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
David Blaine Ridley
Professor of the Practice of Business Administration
David Ridley is the Faculty Director for Health Sector Management at Duke University’s
Fuqua School of Business. He studies health care innovation, production, and prices.
David was the lead author of the paper proposing the priority review voucher program
which became law and created a market of more than a b

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info